INTRODUCTION
============

More than 50 years ago, [@B35] made the remarkable discovery that most twin cattle were born with a stable mixture of each other's red cells. [@B12] later found that human leukocyte antigen (HLA) broadly sensitized patients commonly failed to produce antibodies against mismatched non-inherited maternal antigens (NIMA), but were fully capable of producing anti-non-inherited paternal antigens (NIPA). The definition of NIMA or NIPA is based on an offspring-based HLA haplotype that is not inherited from the mother or father, respectively. [@B7] then showed that injection of allogeneic splenocytes from murine fetuses enabled the acceptance of later skin grafts from the same donor. This phenomenon is now referred to as fetomaternal tolerance, and suggests that perinatal exposure to NIMA may affect the developing immune system of neonates. These phenomena have been clinically utilized in organ transplantation and allogeneic hematopoietic stem cell transplantation (HSCT; [@B9]; [@B47]). [@B9] showed the superior graft survival rate in NIMA- compared to NIPA-mismatched renal transplant recipients from sibling donors. Furthermore, [@B47] demonstrated that HSCT from NIMA-mismatched sibling donors showed a lower incidence of severe acute graft-versus-host disease (GVHD) compared with that from the other family donors. [@B19] have demonstrated the feasibility of HLA-haploidentical HSCT from NIMA-mismatched relatives without T cell depletion. These clinical studies have been performed based on the presence of fetomaternal microchimerism as a result of fetomaternal immunological tolerance. Nevertheless, some cases developed severe acute GVHD despite the existence of microchimeric cells ([@B20]). We recently reported that NIMA effects directed toward the major histocompatibility complex (MHC) antigen were divided into immunogenic and tolerogenic reactivities ([@B4]). These effects were correlated with maternal microchimerism. The reactivities were predictable by an MLR-ELISPOT (mixed lymphocyte reaction; enzyme linked immunospot) assay. We found that non-T cell-depleted (TCD) NIMA-mismatched haploidentical HSCT could be performed safely by evaluating the reaction of IFN-γ-producing cells of the donors against NIMA before transplantation.

HISTOCOMPATIBILITY ANTIGENS IN HUMANS AND MICE
==============================================

Alloantigens can be divided into MHC antigen and minor histocompatibility antigen (MiHA), the former being responsible for eliciting the strongest immune responses to allogeneic tissues. The MHC is referred to as the HLA complex in humans and as the H-2 complex in mice (**Table [1](#T1){ref-type="table"}**). The genes related to the HLA system encode a complex array of histocompatibility molecules that play a central role in immune responsiveness and in determining the outcome of HSCT in humans ([@B5]; [@B36]). The primary goal of histocompatibility testing for patients who are undergoing HSCT is the identification of a suitable HLA-matched donor to reduce the risk of post-transplant complications, which may result from HLA incompatibility.

###### 

Histocompatibility antigens in humans and mice.

                                 Human                                                                                                           Mouse
  ------------------------------ --------------------------------------------------------------------------------------------------------------- -------------------------------------
                                                                                                                                                 
  **MHC antigen**                                                                                                                                
  Class I                        A, B, C                                                                                                         K, D, L
  Class II                       DR, DQ, DP                                                                                                      IA, IE
  **MiHA**                                                                                                                                       
  Y chromosome related           SMCY, UTY, DBY, DFFRY, RPS4Y, TMSB4Y                                                                            HY(Smcy), HY(Uty), HY(Dby)
  Autosomal chromosome related   HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, UGT2B17, LRH-1, CTSH, ECGF1, PANE1, SP110, SLC1A5, SLC19A1, P2RX7   H3, H4, H7, H13, H28, H46, H47, H60

The MHC identity of the donor and host is not the sole factor determining the immunological reactivity in HSCT. When transplantation is performed in an unrelated setting, even if the MHC antigens of donor are identical to those of recipient, considerable transplant reactions may occur because of differences at various minor histocompatibility loci. MiHAs, peptides derived from polymorphic proteins, are capable of eliciting cellular alloimmune responses *in vitro* and *in vivo*. Their immunogenicity arises as a result of their presentation in the context of MHC class I or II, where they are recognized by alloreactive MHC-restricted T cells. The most important immune reactions elicited by *in vivo* alloreactivity to MiHA are graft rejection and acute GVHD.

To date, human MiHAs have not been fully characterized, although some murine MiHAs have been compared with the human counterparts (**Table [1](#T1){ref-type="table"}**). Immunological targeting of HY proteins results in a relatively high incidence of acute GVHD when male recipients receive HSCT from female donors ([@B40]). While approximately one-third of the known MiHAs are encoded on the Y chromosome, many MiHAs are located on autosomal chromosomes. A genetic linkage analysis has been used to define the genomic regions encoding the MiHAs ([@B1]; [@B13]). With the recent introduction of more advanced analytical techniques, more human MiHA epitopes have been identified ([@B44]; [@B39]).

CLINICAL SIGNIFICANCE OF NON-INHERITED MATERNAL ANTIGEN
=======================================================

Graft survival in HSCT is optimal when the donor and recipient are HLA-identical. However, in some situations, if this is not possible, haploidentical siblings, parents, and offspring are considered as potential donors. Contact between the mother and child during pregnancy can lead to tolerization, and subsequently have an additional benefit on the transplant outcome. A new nomenclature was proposed to assign the haplotypes of a family in which one of the siblings is a potential transplant donor ([@B46]) as depicted in **Figure [1](#F1){ref-type="fig"}**. The parents or siblings that share one haplotype with the recipient and differ for the other haplotype are potential donors. The patient inherits the inherited maternal HLA antigens (IMA) haplotype from the mother, and the inherited paternal HLA antigens (IPA) from the father. When the patient is transplanted from one of the parents or from a haploidentical sibling, the NIMA or NIPA is the mismatched haplotype. This nomenclature scheme can also be used in cases where the mother or father is the potential donor (**Figure [1](#F1){ref-type="fig"}**). Because of the existence of fetomaternal tolerance, NIPA is more immunogenic than NIMA. Therefore, the order of donor eligibility is IMA/IPA, NIMA/IPA followed by IMA/NIPA.

![**Significance of non-inherited maternal antigen in transplantation**. The nomenclature of the HLA haplotype is patient-oriented in the transplantation field. Children inherit one haplotype from each of parent. Siblings of the patient share one haplotype with the donor, and the other haplotype is the non-inherited haplotype. The HLA haplotypes in parentheses are shown as representative examples. When the patient is transplanted with donor from one of the parents or from a haploidentical sibling, the non-inherited maternal HLA antigens (NIMA) or non-inherited paternal HLA antigens (NIPA) are the mismatched haplotype. The NIMA and NIPA-mismatched siblings can be potential donors.](fimmu-03-00135-g001){#F1}

Several studies have been performed to investigate the influence of non-inherited and inherited parental antigens on transplantation, and tolerizing effects (a NIMA effect) have been described. In HSCT, [@B47] and [@B19] showed that the patients who received non-TCD BMT from a NIMA-mismatched donor had a significantly lower incidence of acute GVHD than a NIPA-mismatched donor. However, even in non-TCD BMT from a NIMA-mismatched donor, 10% of patients still experienced severe acute GVHD ([@B19]). Furthermore, graft rejection and hyperacute GVHD after HSCT from NIMA-mismatched siblings have been observed in spite of the fact that maternal microchimerism was detected ([@B34]). On the other hand, [@B20] described that a substantial proportion of long-term survivors after NIMA-mismatched HSCT could discontinue the administration of immunosuppressive agents, despite the frequent occurrence of moderate to severe chronic GVHD. Therefore, a method that could evaluate this unpredictable NIMA effect was desired.

MURINE MODELS FOR MAJOR AND MINOR HISTOCOMPATIBILITY ANTIGENS TO NIMA
=====================================================================

There have been several investigations of NIMA in murine models ([@B9]; [@B2]). The immunological effects of developmental exposure to NIMA are heterogeneous ([@B29]; [@B31]; [@B49]). The precise mechanisms underlying the heterogeneity are still under investigation. The relevance of MiHA in the NIMA effect has not been reported. Not only in the MHC-identical, but also under MHC-haploidentical conditions, MiHA alloreactivities may be induced upon transplantation ([@B48]). Therefore, focusing on the NIMA effect separated by the MHC (H-2) and MiHA responses is clinically relevant.

The mouse MiHA loci confer a wide range of immunogenicity, ranging from weakly to strongly immunogenic (**Table [1](#T1){ref-type="table"}**; [@B28]; [@B11]; [@B37]). Recent studies have provided evidence that GVHD could be caused by a limited number of MiHA, including H4, H7, H13, H28, H60, and H-Y ([@B14]; [@B10]; [@B51]). The immunodominance of these MiHA was manifested on genetically varied backgrounds among B10, BALB/c, and DBA/2 strains ([@B38]; [@B28]; [@B26]). So far, there has been no report distinguishing H-2 from MiHA with regard to NIMA. We have classified mouse models of NIMA based on the major and minor histocompatibility antigens to NIMA ([@B17]). In our study, B10 congenic mice were used as NIMA models and the MiHA matched entirely in this system (**Figure [2B](#F2){ref-type="fig"}**). On the other hand, in the conventional model (**Figure [2A](#F2){ref-type="fig"}**), the NIMA includes not only non-inherited H-2, but also non-inherited MiHA. Therefore, our NIMA model, but not the conventional NIMA model, did not affect the immunogenicity of MiHA. We examined the tolerogenic potential of NIMA-exposure for H-2 of class I and II disparities without any influences of the MiHA ([@B4]). Contrary to previous reports that showed an apparent NIMA effect ([@B2]; [@B3]), we found no evidence of the NIMA effect ([@B4]). The reason for the difference remains to be determined, but it could be due to the abrogation of the MiHA effect in our system (**Figure [2B](#F2){ref-type="fig"}**).

![**Murine models for non-inherited maternal antigens**. **(A)** *Left*, C57BL/6 (B6) males (H-2^b/b^) were mated with (B6 × DBA/2) F1 females (H-2^b/d^), thus exposing the H-2^b/b^ offspring *in utero* and via breastfeeding to NIMA^d^ antigens. *Right*, (B6 × DBA/2) F1 males were mated with B6 females, creating H-2^b/b^ backcross offspring that had not been exposed to "d," as reported by [@B2]. **(B)** *Left*, B10.BR males (H-2^k^) were mated with (B10.D2 × B10) F1 females (H-2^d/b^), thus exposing the H-2^d/k^ type offspring to NIMA^b^, and H-2^b/k^ type offspring to NIMA^d^. *Right*, (B10.D2 × B10) F1 males (H-2^d/b^) were mated with B10.BR females (H-2^k^), creating the controls; both H-2^d/k^ and H-2^b/k^ type offspring that had not been exposed to "b" and "d," respectively. These mice have a B10 background, in other words, their MiHA are matched, and the H-2 antigens are mismatched for both class I and II.](fimmu-03-00135-g002){#F2}

MATERNAL MICROCHIMERISM AND FETOMATERNAL TOLERANCE
==================================================

The bidirectional exchange of cells, both mature and progenitor types, at the maternal--fetal interface is a common feature of mammalian reproduction ([@B25]). The presence of semiallogeneic cells in a host can have significant immunological effects on transplantation tolerance and rejection. Maternal cells and DNA were detected for a long time after parturition in the peripheral blood and lymphoid organs of offspring ([@B27]; [@B2]). Breastfeeding during the neonatal period also might contribute to building-up maternal microchimerism in the offspring, because breast milk is rich in soluble maternal MHC antigens ([@B49]; [@B3]). Maternal microchimerism may cause tolerance, resulting in the acceptance of an allograft bearing antigens shared by the microchimeric cells. However, microchimerism may also cause sensitization, thus resulting in rejection. Distinguishing which of these effects is likely to occur prior to the transplant may revolutionize the field of living-related renal transplantation, wherein microchimerism can exert a powerful influence on graft outcome ([@B47]). Long-term maternal microchimerism is easily detected from the peripheral blood or various tissues, including the skin, liver, and thyroid gland, by using highly sensitive polymerase chain reaction-based techniques ([@B18]). Although many investigators have suggested the association of long-term maternal and fetal microchimerism with the development of autoimmune diseases, including systemic sclerosis, primary biliary cirrhosis, juvenile inflammatory myopathies, and biliary atresia ([@B33]; [@B41]), it is difficult to establish a precise etiological link, because maternal microchimerism is frequently found in healthy females with a history of uncomplicated pregnancy, and in more than two-thirds of immunocompetent individuals without any manifestations of autoimmune attacks ([@B23]). Moreover, [@B22] suggested that passenger leukocytes were involved in the induction phase of allograft acceptance and microchimerism in the thymus, but not in the blood, and were also associated with allograft survival. These results suggest that microchimerism may play a role in allograft survival, but that the persistence of peripheral microchimerism is not required.

Several mechanisms of fetomaternal tolerance have so far been reported. One possible mechanism is the clonal deletion of NIMA-specific lymphocytes. [@B50] described partial deletion of B cells having high affinity for the NIMA. However, B cells having low affinity for the NIMA were not clonally deleted. [@B6] showed central and peripheral deletion of donor-specific T cells after establishing mixed chimerism in the recipient with a high dose of bone marrow cells. Low doses of bone marrow cells induced a form of tolerance that was regulatory T cells (Treg)-dependent, consistent with the establishment of microchimerism rather than mixed chimerism. [@B8] described that deletion of effector T cells due to a form of suppressive microchimerism in antigen-presenting cells was a consequence of the establishment of a dominant Treg-population in the host. Therefore, fetomaternal tolerance could not be explained only by the clonal deletion mechanism.

Another possible mechanism is the induction of Treg for NIMA. [@B43] described the possibility of inducing NIMA-specific Treg in the direct and indirect presentation of maternal microchimerism. On the other hand, since oral tolerance is known to generate TGF-β-producing Treg ([@B16]), oral exposure to maternal MHC antigens present in breast milk ([@B30]) may generate NIMA-specific Treg, which may prevent the deletion of maternal cells by NIMA-specific effector T cells, resulting in a high level of microchimerism. [@B3] reported that exposure to NIMA both *in utero* and by breastfeeding appears to generate higher levels of maternal microchimerism than *in utero* exposure alone, and that the degree of microchimerism, correlates with a prolonged survival in maternal heart grafts.

PREDICTION OF ACUTE GVHD IN HLA-MISMATCHED HSCT
===============================================

Predicting acute GVHD *in vitro* before transplantation has been tried in an HLA-mismatched setting, but satisfactory methods had not been established. The frequencies of cytotoxic T lymphocyte precursor (CTLp) and helper T lymphocyte precursor (HTLp) cells, as well as MLR, were reported for the methods that had been evaluated to detect an individual's reactivity to NIMA *in vitro* ([@B15]; [@B32]; [@B42]). [@B32] described that the frequency of NIMA-specific CTLp in cord blood samples could be measured in order to better define the phenomenon of NIMA tolerance. NIMA-reactive cord blood cells were detectable, but the authors of that study could not show a difference in the CTLp frequency toward NIMA and NIPA. [@B15] investigated whether NIMA tolerance could allow transplantation over certain HLA barriers. Neither the CTLp nor HTLp frequencies against NIPA were not significantly different from those against NIMA. Indeed, [@B21] showed that the CTLp and HTLp frequencies were not predictive for the risk of acute GVHD in patients who received allogeneic HSCT. Collectively, established test systems are not available for predicting an alloreaction and the outcome after HSCT. CTLp reflects the alloreactivity of class I mismatch, and MLR and HTLp reflect alloreactivity of class II mismatch. [@B24] reported an evaluation of allogeneic reactions that used Treg. They generated carboxyfluorescein diacetate succinimidyl ester-labeled CD4^+^CD25^high^ FOXP3^+^ cells in MLR, which they called "Treg MLR," with varying HLA disparities and cell components. However, this method reflects only differences in MHC class II. Thus, all of the above-mentioned methods can detect MHC class I or class II separately, but it is difficult to detect them simultaneously (**Table [2](#T2){ref-type="table"}**). We recently, reported a novel method, MLR-ELISPOT assay, that overcomes these disadvantages, as shown in **Figure [3A](#F3){ref-type="fig"}**.

###### 

Assays to detect allogeneic antigens.

  **Assay**                                       **Target antigen**
  ----------------------------------------------- ---------------------------
  Frequency of cytotoxic T lymphocyte precursor   MHC class I
  Frequency of helper T lymphocyte precursor      MHC class II
  Mixed lymphocyte reaction (MLR), modified MLR   MHC class II
  Regulatory T lymphocyte MLR                     MHC class II
  MLR-ELISPOT for interferon-γ                    MHC class I and II (MiHA)

![**Prediction of the reactivity to NIMA by the MLR-ELISPOT assay**. **(A)** The ELISPOT assay combined with MLR (MLR-ELISPOT) is a sensitive functional assay to detect alloreactivity for both major and minor histocompatibility antigens in mice. **(B)** The mice were classified into two groups based on their reactivity to NIMA; the high responders (HR ≥ mean ± 1 SD in NIMA-non-exposed) or the low responders (LR \< mean ± 1 SD) group by using MLR (Araki et al., 2010). The IFN-γ-producing ability before the induction of GVHD was presented by the MLR-ELISPOT assay. Peripheral blood mononuclear cells from NIMA-exposed LR mice (*n* = 8), NIMA-exposed HR mice (*n* = 7), and non-exposed mice (*n* = 6) were stimulated with B10 mouse peripheral blood mononuclear cells. The data are expressed as the means ± SD of individual animals. \**p* \< 0.05.](fimmu-03-00135-g003){#F3}

The alloreactivities of NIMA-exposed mice and NIMA-non-exposed mice were evaluated by MLR, and we found a wide range of reactivity ([@B4]). This indicates that the fetomaternal interaction acts on both tolerance (low-responder, LR) and sensitization (high-responder, HR; [@B31]; [@B45]). The reports from [@B15] and [@B42] detected a reactivity to NIMA by MLR, and CTLp and HTLp, respectively. Interestingly, when we scrutinized the figures in their articles, the individual reactivities of the NIMA-exposed group showed a wider range than the control group, and those reactivities seem to be divided into low and high reactions, although the authors of those studies did not discuss these observations. This was a further indication that reactivity to NIMA could be detected *in vitro*, and that the fetomaternal interaction promoted either tolerance or sensitization.

Recently, we demonstrated that the number of cells producing IFN-γ was significantly lower in the NIMA-exposed LR group than the HR group by using an MLR-ELISPOT assay in a murine model (**Figure [3B](#F3){ref-type="fig"}**). Thus, the capacity for an individual to produce IFN-γ against allogeneic antigens or NIMA could differentiate LR from HR. This assay is easily applicable in humans, and is a versatile method to detect reactivities to MHC class I, as well as class II. Moreover, its detection may reflect the reactivity to MiHA. In other words, this assay might be useful to predict the total immunological reaction of donor T cells to the recipient in HLA-mismatched HSCT.

CONCLUSION
==========

Non-inherited maternal antigens-mismatched haploidentical HSCT has been progressing, and now can lead to sustained engraftment, lower early treatment-related mortality, and acceptable rates of acute GVHD. However, it is difficult to predict severe acute GVHD prior to transplantation. Our recent report addressed this issue ([@B4]). The NIMA effect directed toward MHC antigens was divided into immunogenic and tolerogenic reactivities. There was an unevenness in the acquisition and maintenance of microchimerism in offspring, which was not due solely to differences in MHC gene inheritance. Although T cell replete haploidentical transplantation is performed only when there is positive microchimerism, the individual reactivity of the donor is not evaluated at present. Therefore, our study is clinically relevant, and T cell replete NIMA-mismatched haploidentical transplantation can be performed more safely in the future by evaluating the responses of the IFN-γ-producing cells of the donor against NIMA.
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